Physician profile
Riley Close
NPI 1942809751
$1,408.47
in general payments reported to CMS, 2019-2025
13 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.00 · 2022: $162 · 2023: $419 · 2024: $312 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $338.20 | 2021-2025 | Lifevest |
| Medtronic, INC. | $245.64 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Azure Xt Dr Mri Surescan, Micra |
| Merck Sharp & Dohme LLC | $198.49 | 2023-2025 | Verquvo, Capvaxive |
| Actelion Pharmaceuticals US, INC. | $157.78 | 2023-2024 | Uptravi, Opsumit |
| Atricure, INC. | $127.58 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Novartis Pharmaceuticals Corporation | $105.01 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $74.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $45.50 | 2023-2024 | Eliquis, Camzyos |
| Bridgebio Pharma, INC. | $42.02 | 2025 | Attruby |
| Daiichi Sankyo INC. | $21.35 | 2023 | Injectafer |
| Cvrx, INC. | $21.17 | 2025 | Barostim Neo System |
| Amgen INC. | $15.61 | 2024 | Repatha |
| Baxter Healthcare | $15.13 | 2025 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riley Close listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.